Isolation of a 177Hf Complex Formed by β-Decay of a 177Lu-Labeled Radiotherapeutic Compound and NMR Structural Elucidation of the Ligand and its Lu and Hf Complexes
- 25 February 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 48 (7) , 3114-3124
Abstract
177Lu-AMBA (AMBA = DO3A-CH2CO-G-[4-aminobenzoyl]-QWAVGHLM-NH2) is being developed for the radiotherapeutic treatment of tumors that express the gastrin-releasing peptide receptor (GRP-R). In this study we investigated the fate of the 177hafnium (177Hf) that forms upon the decay of 177Lu while the latter is complexed with AMBA. When decayed solutions of 177Lu-AMBA were analyzed, it was found that 177Hf is retained in the DO3A monoamide chelator, forming a pair of interconverting isomers. We report the synthesis and full characterization of natLu-AMBA and the studies performed to demonstrate its correspondence to radioactive 177Lu-AMBA. We also report the synthesis and characterization of Hf-AMBA and, by NMR studies, show structural analogies between Hf-AMBA, its parent compound Lu-AMBA, and the unmetallated AMBA ligand. In the NMR spectra of both the metallated and unmetallated AMBA ligand, a stacking interaction between the amino benzoyl residue in the linker and a tryptophan in the truncated bombesin [BBN(7-14)-NH2] peptide targeting group was found.Keywords
This publication has 30 references indexed in Scilit:
- Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumorsApplied Radiation and Isotopes, 2008
- 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapyNuclear Medicine and Biology, 2004
- Detection of Colon Cancer with 99m Tc-Labeled Bombesin Derivative ( 99m Tc-leu13-BN1)Cancer Biotherapy and Radiopharmaceuticals, 2004
- Peptide Receptors as Molecular Targets for Cancer Diagnosis and TherapyEndocrine Reviews, 2003
- Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activitiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Comparison of Yttrium and Indium Complexes of DOTA-BA and DOTA-MBA: Models for 90Y- and 111In-Labeled DOTA−Biomolecule ConjugatesBioconjugate Chemistry, 2002
- Reactor-produced radionuclides at the University of Missouri Research ReactorApplied Radiation and Isotopes, 1998
- Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound 125I‐(Tyr4) bombesin by tumor cellsThe Prostate, 1994
- Chemical and biological consequences of ?-decayRadiation and Environmental Biophysics, 1977